Tom Thurén

20.2k total citations · 3 hit papers
58 papers, 4.5k citations indexed

About

Tom Thurén is a scholar working on Molecular Biology, Surgery and Biochemistry. According to data from OpenAlex, Tom Thurén has authored 58 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 15 papers in Surgery and 14 papers in Biochemistry. Recurrent topics in Tom Thurén's work include Lipid metabolism and biosynthesis (13 papers), Inflammasome and immune disorders (10 papers) and Lipid Membrane Structure and Behavior (8 papers). Tom Thurén is often cited by papers focused on Lipid metabolism and biosynthesis (13 papers), Inflammasome and immune disorders (10 papers) and Lipid Membrane Structure and Behavior (8 papers). Tom Thurén collaborates with scholars based in United States, Finland and Switzerland. Tom Thurén's co-authors include Paul M. Ridker, Peter Libby, Robert J. Glynn, Jean MacFadyen, Andrew Zalewski, Giulia Renda, Campbell P. Howard, Jorma A. Virtanen, Paavo K.J. Kinnunen and Verena Walter and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Annals of Internal Medicine.

In The Last Decade

Tom Thurén

58 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

2011 609 citations Paul M. Ridker, Tom Thurén et al. profile →
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure

2019 458 citations Brendan M. Everett, Jan H. Cornel et al. Circulation profile →
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)

2018 395 citations Paul M. Ridker, Peter Libby et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Thurén United States	29	1.8k	1.2k	1.0k	992	990	58	4.5k
Eva Hurt‐Camejo Sweden	42	1.8k 1.0×	1.2k 0.9×	1.5k 1.5×	793 0.8×	623 0.6×	92	4.8k
Junichi Masuda Japan	38	1.1k 0.6×	731 0.6×	910 0.9×	1.0k 1.0×	604 0.6×	161	4.8k
José Luis Martín‐Ventura Spain	49	2.6k 1.4×	1.8k 1.5×	1.7k 1.6×	835 0.8×	1.3k 1.3×	189	7.2k
Joy S. Frank United States	27	1.8k 1.0×	971 0.8×	1.8k 1.8×	484 0.5×	888 0.9×	40	4.6k
Mary G. Sorci‐Thomas United States	38	1.8k 1.0×	1.0k 0.8×	1.8k 1.8×	559 0.6×	462 0.5×	85	4.4k
Jan Hinrich Bräsen Germany	35	2.0k 1.1×	1.2k 1.0×	1.1k 1.1×	539 0.5×	600 0.6×	134	5.4k
Colin H. Macphee United States	41	2.6k 1.4×	1.2k 1.0×	2.5k 2.4×	1.7k 1.8×	851 0.9×	90	7.1k
Debra L. Rateri United States	41	1.0k 0.6×	1.4k 1.1×	1.3k 1.3×	438 0.4×	1.3k 1.3×	67	5.1k
Óscar Lorenzo Spain	42	2.4k 1.3×	798 0.6×	802 0.8×	637 0.6×	2.3k 2.4×	110	6.3k
Reijo Laaksonen Finland	39	2.6k 1.4×	499 0.4×	1.5k 1.5×	582 0.6×	947 1.0×	162	5.5k

Countries citing papers authored by Tom Thurén

Since Specialization

Citations

This map shows the geographic impact of Tom Thurén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Thurén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Thurén more than expected).

Fields of papers citing papers by Tom Thurén

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Thurén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Thurén. The network helps show where Tom Thurén may publish in the future.

Co-authorship network of co-authors of Tom Thurén

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Thurén. A scholar is included among the top collaborators of Tom Thurén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Thurén. Tom Thurén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Everett, Brendan M., Jean MacFadyen, Tom Thurén, et al.. (2020). Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. Journal of the American College of Cardiology. 76(14). 1660–1670. 139 indexed citations

Everett, Brendan M., Jan H. Cornel, Mitja Lainščak, et al.. (2019). Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 139(10). 1289–1299. 458 indexed citations breakdown →

Ridker, Paul M., Jean MacFadyen, Robert J. Glynn, et al.. (2018). Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology. 71(21). 2405–2414. 206 indexed citations

Renda, Giulia, Marc Y. Donath, Aruna D. Pradhan, et al.. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology. 71(21). 2392–2401. 248 indexed citations

Howard, Campbell P., Adele Noè, Andrej Skerjanec, et al.. (2014). Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovascular Diabetology. 13(1). 94–94. 44 indexed citations

Hensen, J., Campbell P. Howard, Verena Walter, & Tom Thurén. (2013). Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes & Metabolism. 39(6). 524–531. 91 indexed citations

Ridker, Paul M., Campbell P. Howard, Verena Walter, et al.. (2012). Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen. Circulation. 126(23). 2739–2748. 430 indexed citations

Thurén, Tom, et al.. (1993). Regulation of rat hepatic lipase by the composition of monomolecular films of lipid. Biochemistry. 32(22). 5752–5758. 9 indexed citations

Thurén, Tom, Karl H. Weisgraber, Patricia Sisson, & Moseley Waite. (1992). Role of apolipoprotein E in hepatic lipase-catalyzed hydrolysis of phospholipid in high-density lipoproteins. Biochemistry. 31(8). 2332–2338. 61 indexed citations

10.

Waite, Moseley, et al.. (1992). Action of lysosomal phospholipase A1 on bis(monoacylglycerol)phosphate. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1128(2-3). 281–284. 2 indexed citations

11.

Thurén, Tom & Paavo K.J. Kinnunen. (1991). A continuous fluorometric assay for phospholipase C from Clostridium perfringens. Chemistry and Physics of Lipids. 59(1). 69–74. 5 indexed citations

12.

Thurén, Tom, Kari K. Eklund, Jorma A. Virtanen, & Paavo K.J. Kinnunen. (1990). Hydrolysis of supported pyrenephospholipid monolayers by phospholipase A2. Chemistry and Physics of Lipids. 55(1). 55–60. 2 indexed citations

13.

Thurén, Tom, Patricia Sisson, & Moseley Waite. (1990). Hydrolysis of lipid mixtures by rat hepatic lipase. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1046(2). 178–184. 16 indexed citations

14.

Tj, Nevalainen, et al.. (1990). Increased serum phospholipase A2 activity in schizophrenia: a replication study.. PubMed. 28(6). 495–501. 152 indexed citations

15.

Pulkkinen, M.O., et al.. (1990). Pancreatic and Catalytic Phospholipase A<sub>2</sub> in Relation to Pregnancy, Labor and Fetal Outcome. Gynecologic and Obstetric Investigation. 29(2). 104–107. 6 indexed citations

16.

Nordback, Isto, O Auvinen, T. Koivula, et al.. (1989). Human Pancreatic Phospholipase A<sub>2 </sub> in Acute Necrotizing Pancreatitis. Digestion. 42(3). 128–134. 11 indexed citations

17.

Thurén, Tom, Jorma A. Virtanen, Pentti Somerharju, & Paavo K.J. Kinnunen. (1988). Phospholipase A2 assay using an intramolecularly quenched pyrene-labeled phospholipid analog as a substrate. Analytical Biochemistry. 170(1). 248–255. 28 indexed citations

18.

Thurén, Tom. (1988). A model for the molecular mechanism of interfacial activation of phospholipase A₂ supporting the substrate theory. FEBS Letters. 229(1). 95–99. 26 indexed citations

19.

Thurén, Tom, et al.. (1987). Triggering of the activity of phospholipase A2 by an electric field. Biochemistry. 26(16). 4907–4910. 55 indexed citations

20.

Thurén, Tom, Jorma A. Virtanen, & Paavo K.J. Kinnunen. (1987). Control of the action of phospholipases A by "vertical compression" of the substrate monolayer. Biochemistry. 26(18). 5816–5819. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact